Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in MSI-H/dMMR/Hypermutated Uterine Cancer
NCT03241745Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Aug 2017
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in uterine cancer, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Progression-Free Survival at 24 weeks. Started Aug 2017; status: completed.
02
Drugs
03
Conditions
uterine cancer
Beyond the preview
Go deeper on NCT03241745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03241745.